Institution
Purdue Pharma
Company•Pickering, Ontario, Canada•
About: Purdue Pharma is a company organization based out in Pickering, Ontario, Canada. It is known for research contribution in the topics: Buprenorphine & Chronic pain. The organization has 622 authors who have published 691 publications receiving 31545 citations. The organization is also known as: Purdue Pharmaceuticals L.P..
Topics: Buprenorphine, Chronic pain, Oxycodone, Hydrocodone, Controlled release
Papers published on a yearly basis
Papers
More filters
••
Cardiff University1, University of Michigan2, University of Washington3, University of Rochester4, University of Toronto5, University of Maryland, Baltimore6, Tufts University7, University of Leeds8, University of Pennsylvania9, Harvard University10, Queen's University11, Pfizer12, Duke University13, United States Army Medical Research and Materiel Command14, Purdue Pharma15, Yale University16, United States Department of Veterans Affairs17, Ford Motor Company18, Stanford University19, Veterans Health Administration20, Mayo Clinic21, University of Ottawa22, University of Pittsburgh23, National Institutes of Health24
TL;DR: Support is provided for the use of reliable and valid PROs and performance-based measures of physical functioning, covering broad aspects of functioning, including work participation, social participation, and caregiver burden, which researchers should consider when designing chronic pain clinical trials.
Abstract: Although pain reduction is commonly the primary outcome in chronic pain clinical trials, physical functioning is also important. A challenge in designing chronic pain trials to determine efficacy and effectiveness of therapies is obtaining appropriate information about the impact of an intervention on physical function. The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) and Outcome Measures in Rheumatology (OMERACT) convened a meeting to consider assessment of physical functioning and participation in research on chronic pain. The primary purpose of this article is to synthesize evidence on the scope of physical functioning to inform work on refining physical function outcome measurement. We address issues in assessing this broad construct and provide examples of frequently used measures of relevant concepts. Investigators can assess physical functioning using patient-reported outcome (PRO), performance-based, and objective measures of activity. This article aims to provide support for the use of these measures, covering broad aspects of functioning, including work participation, social participation, and caregiver burden, which researchers should consider when designing chronic pain clinical trials. Investigators should consider the inclusion of both PROs and performance-based measures as they provide different but also important complementary information. The development and use of reliable and valid PROs and performance-based measures of physical functioning may expedite development of treatments, and standardization of these measures has the potential to facilitate comparison across studies. We provide recommendations regarding important domains to stimulate research to develop tools that are more robust, address consistency and standardization, and engage patients early in tool development.
133 citations
••
TL;DR: The Benefit Risk Action Team framework is a set of processes and tools for selecting, organizing, summarizing, and interpreting data that is relevant to decisions based on benefit–risk assessments that provides a standardized yet flexible platform for incorporating study outcomes and preference weights.
Abstract: The current process of benefit–risk assessment of medicines relies primarily on intuitive expert judgment. Frameworks are needed for transparent, rational and defensible decision making that benefits patients, drug developers, and decision makers. The Benefit Risk Action Team framework is a set of processes and tools for selecting, organizing, summarizing, and interpreting data that is relevant to decisions based on benefit–risk assessments. It provides a standardized yet flexible platform for incorporating study outcomes and preference weights as well as for communicating the rationales for decisions.
Clinical Pharmacology & Therapeutics (2011) 89 2, 312–315. doi:10.1038/clpt.2010.291
122 citations
•
20 Dec 1996TL;DR: In this article, 4-substituted piperidine analogs are used as selectively active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, anxiety, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headaches, glaucoma, CMV retinitis, chronic pain, opioid tolerance or withdrawals, or neurodegenerative disorders.
Abstract: Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 4-substituted piperidine analogs as selectively active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, anxiety, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headaches, glaucoma, CMV retinitis, chronic pain, opioid tolerance or withdrawals, or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described. Also described are novel methods for preparing 4-substituted piperidine analogs and novel intermediates of the 4-substituted piperidine analogs.
120 citations
•
06 Aug 2002TL;DR: In this article, an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an ineffective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering is described.
Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.
118 citations
••
TL;DR: It is confirmed that varicella vaccine is effective at preventing chicken pox, with no waning noted over a 14-year period, and the study data suggest thatvaricella vaccination may reduce the risks of HZ in vaccinated children.
Abstract: BACKGROUND: Varicella vaccine was licensed in the United States in 1995 for individuals ≥12 months of age. A second dose was recommended in the United States in June 2006. Varicella incidence and vaccine effectiveness were assessed in a 14-year prospective study conducted at Kaiser Permanente Northern California. METHODS: A total of 7585 children vaccinated with varicella vaccine in their second year of life in 1995 were followed up prospectively for breakthrough varicella and herpes zoster (HZ) through 2009. A total of 2826 of these children received a second dose in 2006–2009. Incidences of varicella and HZ were estimated and compared with prevaccine era rates. RESULTS: In this cohort of vaccinated children, the average incidence of varicella was 15.9 per 1000 person-years, nine- to tenfold lower than in the prevaccine era. Vaccine effectiveness at the end of the study period was 90%, with no indication of waning over time. Most cases of varicella were mild and occurred early after vaccination. No child developed varicella after a second dose. HZ cases were mild, and rates were lower in the cohort of vaccinated children than in unvaccinated children during the prevaccine era (relative risk: 0.61 [95% confidence interval: 0.43–0.89]). CONCLUSIONS: This study confirmed that varicella vaccine is effective at preventing chicken pox, with no waning noted over a 14-year period. One dose provided excellent protection against moderate to severe disease, and most cases occurred shortly after the cohort was vaccinated. The study data also suggest that varicella vaccination may reduce the risks of HZ in vaccinated children.
117 citations
Authors
Showing all 622 results
Name | H-index | Papers | Citations |
---|---|---|---|
Gideon Koren | 129 | 1994 | 81718 |
Asbjørn Mohr Drewes | 67 | 656 | 17287 |
Hilary L. Surratt | 44 | 169 | 7586 |
Ronald M. Burch | 42 | 108 | 5897 |
John F. W. Keana | 41 | 234 | 6349 |
Sui Xiong Cai | 39 | 91 | 4492 |
Howard D. Chilcoat | 39 | 91 | 8739 |
Sidney H. Schnoll | 37 | 88 | 5336 |
Paul Coplan | 36 | 121 | 4149 |
Benjamin Oshlack | 32 | 95 | 3902 |
Nabarun Dasgupta | 30 | 100 | 3366 |
Donald J. Kyle | 29 | 150 | 2390 |
Nancy C. Lan | 29 | 50 | 3597 |
Christopher D. Breder | 28 | 50 | 6748 |
Michael F. Schneider | 27 | 53 | 4862 |